Aripiprazole CAS 129722-12-9 Purity >99.0% (HPLC) API

Aripiprazole (CAS: 129722-12-9) is a new kind of highly lipid soluble quinoline derivatives, its pharmacological effects characteristic is that it is not only the postsynaptic dopamine D2 receptor antagonist, but also the presynaptic dopamine D2 receptor agonist,it can also excite D1, D3, D4 receptors. Aripiprazole is a second generation atypical antipsychotic and anti-depressant with partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Ki values are 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively, for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors. Aripiprazole is used for the treatment of schizophrenia and related psychotic disorders. Bristol-Myers Squibb and Otsuka Pharmaceutical Company announced that the European Union has approved Abilify (Aripiprazole) in the treatment of schizophrenia listing application. Schizophrenia affects 1% of the global population, and more in young adults. Schizophrenia affects thinking, emotional control and decision-making ability of the patient. Schizophrenia-positive patients will have symptoms such as hallucinations and delusions, patients with negative symptoms are social withdrawal, lack of emotional changes. In 2002 the FDA approved Abilify for the treatment of schizophrenia, which has five dosage strengths: 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, since its approval.